Vascular effects of arginine vasopressin, angiotensin II, and norepinephrine in adrenal insufficiency.

Vascular effects of arginine vasopressin, angiotensin II, and norepinephrine in adrenal insufficiency. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Vascular effects of arginine vasopressin, angiotensin II, and norepinephrine in adrenal insufficiency. Abstract Text:

Plasma arginine vasopressin (AVP) levels were 9.6 pg/ml in the mineralocorticoid-deficient rats, a value significantly greater than 4.8 pg/ml in the glucocorticoid-deficient rats (P less than 0.05), and 1.6 pg/ml in controls (P less than 0.001). The AVP antagonist of the vascular effect of AVP, [1(beta-mercapto-beta, beta-cyclopentamethylenepropionic acid), 2-(O-methyl)tyrosine] AVP, [d(CH2)5Tyr(Me)AVP] (5 micrograms/kg), decreased mean arterial pressure (MAP) from 76.5 to 71.6 mmHg (P less than 0.01) in mineralocorticoid-deficient rats on day 10 but not in glucocorticoid deficient rats on day 14 (113.2-111.6 mmHg, NS) or in control rats (109.7-110.2 mmHg, NS). Plasma renin activity was 40.7 ng X ml-1 X h-1 in mineralocorticoid-deficient rats and 7.2 in glucocorticoid-deficient rats (P less than 0.001). The angiotensin II antagonist, [Sar1-Gly8]angiotensin II (5 micrograms X kg-1 X min-1), decreased MAP from 69.3 to 53.2 mmHg in mineralocorticoid-deficient rats (P less than 0.001) but not in glucocorticoid-deficient rats. Plasma norepinephrine was 1,138 pg/ml in mineralocorticoid-deficient rats and 251 pg/ml in glucocorticoid-deficient rats (P less than 0.001). The alpha-adrenergic blocker, phenoxybenzamine (3 mg/kg), reduced MAP from 82 to 51 mmHg in mineralocorticoid deficient rats (P less than 0.005), a decrease in MAP greater (P less than 0.05) than that observed in glucocorticoid-deficient rats (107.7-84.8 mmHg, P less than 0.02). In addition, the AVP antagonist caused a greater and more prolonged reduction in MAP in mineralocorticoid-deficient rats after the administration of either the angiotensin II antagonist or alpha-blocker. These results indicate that AVP, norepinephrine, and angiotensin II are involved in maintaining blood pressure in the mineralocorticoid-deficient state.

Vascular effects of arginine vasopressin, angiotensin II, and norepinephrine in adrenal insufficiency. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Vascular effects of arginine vasopressin, angiotensin II, and norepinephrine in adrenal insufficiency. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: The American journal of physiology

VOLUME: 246

Page Numbers: H104-13

Journal Abbreviation: Am. J. Physiol.

ISSN: 0002-9513

DAY: 16

MONTH: Jan

YEAR: 1984

Vascular effects of arginine vasopressin, angiotensin II, and norepinephrine in adrenal insufficiency. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370511

Vascular effects of arginine vasopressin, angiotensin II, and norepinephrine in adrenal insufficiency. Keywords Mesh Terms:

KEYWORDS: Saralasin

MESH TERMS: pharmacology

Chemical & Substance for Abstract: Vascular effects of arginine vasopressin, angiotensin II, and norepinephrine in adrenal insufficiency. Information

Substance Name: Renin

Registry Number: EC 3.4.23.15

Grant and Affiliation Information for Vascular effects of arginine vasopressin, angiotensin II, and norepinephrine in adrenal insufficiency.

AFFILIATION:

Country: UNITED STATES

AGENCY: United States NIADDK

GRANT: AM-19928

ACRONYM: AM

MEDLINETA: Am J Physiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Vascular effects of arginine vasopressin, angiotensin II, and norepinephrine in adrenal insufficiency Related Publications

• Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/single-stranded conformation polymorphism analysis.
• Aquaporin-related disorders of water homeostasis.
• Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome.
• Calcium channel blockers: protective effects in ischemic acute renal failure.
• Decreased effective blood volume in edematous disorders: what does this mean?
• Developments in the management of autosomal dominant polycystic kidney disease.
• Efficient Synthetic Access to a New Family of Highly Potent Bryostatin Analogues via a Prins-Driven Macrocyclization Strategy.
• Endotoxemia-related acute kidney injury in transgenic mice with endothelial overexpression of GTP cyclohydrolase-1.
• Further in vivo evidence for antagonist-to-antidiuretic action of arginine vasopressin.
• Hyperosmolality in vivo upregulates aquaporin 2 water channel and Na-K-2Cl co-transporter in Brattleboro rats.
• Induced alterations in calcium uptake rate in normoxic rate proximal tubules.
• Molecular mechanisms of antidiuretic effect of oxytocin.
• Molecular mechanisms of clinical concentrating and diluting disorders.
• Nepafenac-associated corneal melt.
• Nitric oxide synthase inhibition and acute renal ischemia: effect on systemic hemodynamics and mortality.
• Polyuria of thyrotoxicosis: downregulation of aquaporin water channels and increased solute excretion.
• Potential pharmacological interventions in polycystic kidney disease.
• Prostacyclin in endotoxemia-induced acute kidney injury: cyclooxygenase inhibition and renal prostacyclin synthase transgenic mice.
• Relationship between urinary albumin excretion and left ventricular mass with mortality in patients with type 2 diabetes.
• Role of AQP1 in endotoxemia-induced acute kidney injury.
• Sarcoidosis of the nervous system.
• The role of calcium in the pathogenesis of acute renal failure.
• The role of the calcium-dependent enzymes nitric oxide synthase and calpain in hypoxia-induced proximal tubule injury.
• The sea within us: disorders of body water homeostasis.
• Therapy of acute myelocytic leukemia. Daunomycin contrasted with a combination of cytosine arabinoside and 6-thioguanine.
• Tribromethanol (Avertin).
• Variation in age at ESRD in autosomal dominant polycystic kidney disease.
• Vascular effects of arginine vasopressin, angiotensin II, and norepinephrine in adrenal insufficiency.
• Vascular effects of arginine-vasopressin, angiotensin and noradrenaline in adrenal insufficiency.
• Vasopressin and aquaporin 2 in clinical disorders of water homeostasis.